FDA: Master protocols have value in COVID-19, and beyond
Regulatory NewsJoanne S. Eglovitch
Clinical TrialsComplianceNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchClinical TrialsComplianceNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy